KR20220086563A - 페로포틴 억제제(vit-2763)를 사용한 겸상적혈구병을 치료하기 위한 방법 및 조성물 - Google Patents

페로포틴 억제제(vit-2763)를 사용한 겸상적혈구병을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20220086563A
KR20220086563A KR1020227012237A KR20227012237A KR20220086563A KR 20220086563 A KR20220086563 A KR 20220086563A KR 1020227012237 A KR1020227012237 A KR 1020227012237A KR 20227012237 A KR20227012237 A KR 20227012237A KR 20220086563 A KR20220086563 A KR 20220086563A
Authority
KR
South Korea
Prior art keywords
compound
group
treatment
scd
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012237A
Other languages
English (en)
Korean (ko)
Inventor
바니아 마놀로바
프란츠 닥터 뒤렌베르거
나자 니페네거
Original Assignee
비포르 (인터내셔날) 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비포르 (인터내셔날) 아게 filed Critical 비포르 (인터내셔날) 아게
Publication of KR20220086563A publication Critical patent/KR20220086563A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
KR1020227012237A 2019-10-22 2020-10-22 페로포틴 억제제(vit-2763)를 사용한 겸상적혈구병을 치료하기 위한 방법 및 조성물 Pending KR20220086563A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
EP19000483.8 2019-10-22
US62/924,556 2019-10-22
EP20163777 2020-03-17
EP20163777.4 2020-03-17
EP20176336.4 2020-05-25
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (1)

Publication Number Publication Date
KR20220086563A true KR20220086563A (ko) 2022-06-23

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012237A Pending KR20220086563A (ko) 2019-10-22 2020-10-22 페로포틴 억제제(vit-2763)를 사용한 겸상적혈구병을 치료하기 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US20220274973A1 (https=)
EP (1) EP4048262A1 (https=)
JP (1) JP7594004B2 (https=)
KR (1) KR20220086563A (https=)
CN (1) CN114765955B (https=)
AU (1) AU2020369137A1 (https=)
BR (1) BR112022007616A2 (https=)
CA (1) CA3154524A1 (https=)
IL (1) IL291137A (https=)
MX (1) MX2022004806A (https=)
WO (1) WO2021078889A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025535398A (ja) 2022-10-21 2025-10-24 ビフォー （インターナショナル） エージー 二環式フェロポーチン阻害剤
EP4731218A1 (en) 2023-06-26 2026-04-29 Vifor (International) AG Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
JOP20180036A1 (ar) * 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Also Published As

Publication number Publication date
JP2023500060A (ja) 2023-01-04
CA3154524A1 (en) 2021-04-21
IL291137A (en) 2022-05-01
US20220274973A1 (en) 2022-09-01
JP7594004B2 (ja) 2024-12-03
WO2021078889A1 (en) 2021-04-29
AU2020369137A1 (en) 2022-04-07
CN114765955B (zh) 2025-06-24
EP4048262A1 (en) 2022-08-31
MX2022004806A (es) 2022-05-16
BR112022007616A2 (pt) 2022-07-12
CN114765955A (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
AU2018203357C1 (en) New methods
Paesano et al. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women
JP7561180B2 (ja) 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤
JP7594004B2 (ja) フェロポーチン阻害剤（ｖｉｔ－２７６３）を用いる鎌状赤血球症を治療するための方法及び組成物
AU2020316632B2 (en) Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (TDT)
KR20230134476A (ko) 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
EP3065728A1 (en) Novel methods
EA048997B1 (ru) Способы и композиции для лечения серповидно-клеточной болезни ингибитором ферропортина (vit-2763)
US20140350097A1 (en) Treatment of hypotension associated with hemodialysis
EP2026801B1 (en) Deferasirox for the treatment of hereditary hemochromatosis
CN116710091A (zh) 用于治疗骨髓增生异常综合征(mds)的膜铁转运蛋白抑制剂
EA049341B1 (ru) Применение ингибиторов ферропортина для лечения миелодиспластических синдромов (мдс)
EA047958B1 (ru) Ингибиторы ферропортина для применения с целью предупреждения и лечения повреждений почек
EA048075B1 (ru) Ингибиторы ферропортина для применения при лечении трансфузионно-зависимой бета-талассемии (tdt)
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902